TNF and inflammatory bowel disease: Immunosuppressed IBD patients without a previous SARS-CoV-2 infection exhibited a significantly reduced humoral immunity (anti-S-IgG, sVNT) compared to healthy control individuals, particularly patients under anti-TNF therapy.